Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus
| Autor: | Annaswamy Raji, Hakima Hannachi, Annpey Pong, Steven G. Terra, Jie Liu, Steven B. Heymsfield, Silvina Gallo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Endocrinology Diabetes and Metabolism Medicine (miscellaneous) 030209 endocrinology & metabolism Overweight Placebo Gastroenterology 03 medical and health sciences 0302 clinical medicine Endocrinology Internal medicine Diabetes mellitus medicine Humans 030212 general & internal medicine Obesity Clinical Trials and Investigations Adverse effect Sodium-Glucose Transporter 2 Inhibitors Nutrition and Dietetics business.industry Incidence (epidemiology) Type 2 Diabetes Mellitus nutritional and metabolic diseases Original Articles Middle Aged medicine.disease Bridged Bicyclo Compounds Heterocyclic Blood pressure Diabetes Mellitus Type 2 Original Article Female medicine.symptom business |
| Zdroj: | Obesity (Silver Spring, Md.) |
| ISSN: | 1930-739X 1930-7381 |
| Popis: | OBJECTIVE This study aimed to evaluate ertugliflozin in patients with overweight and obesity with type 2 diabetes mellitus. METHODS Data from three placebo-controlled, randomized, Phase 3 studies were pooled. Patients with baseline BMI ≥ 25 (1,377/1,544; 89%) were assessed with a stratification by BMI subgroup. RESULTS At week 26, reductions from baseline in glycated hemoglobin A1c (HbA1c), fasting plasma glucose, body weight (BW), and systolic blood pressure (SBP) were greater with ertugliflozin versus placebo. For placebo, ertugliflozin 5 mg, and ertugliflozin 15 mg, respectively, least squares mean change was 0.1%, -0.8%, and -0.9% for HbA1c and -1.2 kg, -3.1 kg, and -3.2 kg for BW. HbA1c reductions were consistent across BMI subgroups. For ertugliflozin 5 mg and 15 mg, least squares mean change (placebo adjusted) in absolute BW was -1.4 kg and -1.2 kg for BMI 25 to |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text